speb/financial-data huggingface dataset:
NATH cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 2542000.00
NATH income_statement (annual, 2026-03-31) — Operating Income: 30102000.00
NATH income_statement (quarterly, 2026-03-31) — Operating Income: 4682000.00
NATH income_statement (annual, 2026-03-31) — Operating Revenue: 162063000.00
NATH income_statement (quarterly, 2026-03-31) — Operating Revenue: 35066000.00
NATH balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 4094405.00
NATH balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 4094405.00
NATH balance_sheet (annual, 2026-03-31) — Other Current Assets: 392000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 392000.00
NATH balance_sheet (annual, 2026-03-31) — Other Current Borrowings: 2400000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 2400000.00
NATH balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 304000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 304000.00
NATH income_statement (annual, 2026-03-31) — Other Gand A: 17903000.00
NATH income_statement (quarterly, 2026-03-31) — Other Gand A: 6105000.00
NATH income_statement (annual, 2026-03-31) — Other Income Expense: 165000.00
NATH income_statement (quarterly, 2026-03-31) — Other Income Expense: 0.00
NATH balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 348000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 348000.00
NATH cash_flow (annual, 2026-03-31) — Other Non Cash Items: -123000.00
NATH cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: -32000.00
NATH balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 85000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 85000.00
NATH balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 717000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 717000.00
NATH income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 165000.00
NATH income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 0.00
NATH balance_sheet (annual, 2026-03-31) — Other Properties: 3672000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Properties: 3672000.00
NATH balance_sheet (annual, 2026-03-31) — Other Receivables: 191000.00
NATH balance_sheet (quarterly, 2026-03-31) — Other Receivables: 191000.00
NATH balance_sheet (annual, 2026-03-31) — Payables: 7915000.00
NATH balance_sheet (quarterly, 2026-03-31) — Payables: 7915000.00
NATH balance_sheet (annual, 2026-03-31) — Payables And Accrued Expenses: 12751000.00
NATH balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 12751000.00
NATH balance_sheet (annual, 2026-03-31) — Prepaid Assets: 1301000.00
NATH balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 1301000.00
NATH income_statement (annual, 2026-03-31) — Pretax Income: 28190000.00
NATH income_statement (quarterly, 2026-03-31) — Pretax Income: 4164000.00
NATH balance_sheet (annual, 2026-03-31) — Properties: 0.00
NATH balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
NATH cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 129000.00
NATH cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 66000.00
NATH cash_flow (annual, 2026-03-31) — Purchase Of PPE: -370000.00
NATH cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -38000.00
NATH balance_sheet (annual, 2026-03-31) — Receivables: 20132000.00
NATH balance_sheet (quarterly, 2026-03-31) — Receivables: 20132000.00
NATH balance_sheet (annual, 2026-03-31) — Receivables Adjustments Allowances: -777000.00
NATH balance_sheet (quarterly, 2026-03-31) — Receivables Adjustments Allowances: -777000.00
NATH income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 113133000.00
NATH income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 25676000.00
NATH income_statement (annual, 2026-03-31) — Reconciled Depreciation: 925000.00
NATH income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 229000.00
NATH cash_flow (annual, 2026-03-31) — Repayment Of Debt: -2400000.00
NATH cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -600000.00
NATH balance_sheet (annual, 2026-03-31) — Retained Earnings: 8180000.00
NATH balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 8180000.00
NATH income_statement (annual, 2026-03-31) — Selling General And Administration: 17903000.00
NATH income_statement (quarterly, 2026-03-31) — Selling General And Administration: 4479000.00
NATH balance_sheet (annual, 2026-03-31) — Share Issued: 9383920.00
NATH balance_sheet (quarterly, 2026-03-31) — Share Issued: 9383920.00
NATH income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
NATH income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
NATH cash_flow (annual, 2026-03-31) — Stock Based Compensation: 1132000.00
NATH cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 280000.00
NATH balance_sheet (annual, 2026-03-31) — Stockholders Equity: -14223000.00
NATH balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: -14223000.00
NATH balance_sheet (annual, 2026-03-31) — Tangible Book Value: -14666000.00
NATH balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -14666000.00
NATH income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NATH income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NATH income_statement (annual, 2026-03-31) — Tax Provision: 8170000.00
NATH income_statement (quarterly, 2026-03-31) — Tax Provision: 1355000.00
NATH income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.29
NATH income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.33
NATH balance_sheet (annual, 2026-03-31) — Taxes Receivable: 291000.00
NATH balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 291000.00
NATH balance_sheet (annual, 2026-03-31) — Total Assets: 53651000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Assets: 53651000.00
NATH balance_sheet (annual, 2026-03-31) — Total Capitalization: 31520000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 31520000.00
NATH balance_sheet (annual, 2026-03-31) — Total Debt: 52086000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Debt: 52086000.00
NATH balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: -14223000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: -14223000.00
NATH income_statement (annual, 2026-03-31) — Total Expenses: 131961000.00
NATH income_statement (quarterly, 2026-03-31) — Total Expenses: 30384000.00
NATH balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 67874000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 67874000.00
NATH balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 6531000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 6531000.00
NATH balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 48972000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 48972000.00
NATH income_statement (annual, 2026-03-31) — Total Operating Income As Reported: 30102000.00
NATH income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 4682000.00
NATH balance_sheet (annual, 2026-03-31) — Total Tax Payable: 11000.00
NATH balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 11000.00
NATH income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
NATH income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
NATH income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
NATH income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
NATH balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 5289515.00
NATH balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 5289515.00
NATH balance_sheet (annual, 2026-03-31) — Treasury Stock: 86662000.00
NATH balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 86662000.00
NATH balance_sheet (annual, 2026-03-31) — Working Capital: 28218000.00
NATH balance_sheet (quarterly, 2026-03-31) — Working Capital: 28218000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -184033000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 1344225000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -60305000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Amortization: 16055000.00
NATHBIOGEN.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 16055000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 31283000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 41756000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 1980010000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 66454000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 915783000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Interest Income: 10926000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 10926000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Investmentsin Associatesat Cost: 49940000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Investmentsin Joint Venturesat Cost: 152000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 2221073000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Long Term Equity Investment: 49940000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 198265000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Minority Interest: -46000.00
NATHBIOGEN.NS cash_flow (annual, 2022-03-31) — Net Intangibles Purchase And Sale: -130000.00
NATHBIOGEN.NS cash_flow (annual, 2022-03-31) — Net Other Financing Charges: 240000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 26106000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 6859000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Other Payable: 257413000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 467000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Other Special Charges: 886415000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 10833000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 1504959000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
NATHBIOGEN.NS cash_flow (annual, 2022-03-31) — Purchase Of Intangibles: -130000.00
NATHBIOGEN.NS cash_flow (annual, 2022-03-31) — Purchase Of Investment: -3000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 61183000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 30344000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 114416000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Research And Development: 88852000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 50000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 3744309000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 5185000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Trading Securities: 49940000.00
NATHBIOGEN.NS balance_sheet (annual, 2022-03-31) — Work In Process: 162234000.00
NATHBIOGEN.NS income_statement (annual, 2022-03-31) — Write Off: 75000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — +Operating Expense: 1407152000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — +Total Revenue: 3013637000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 277356000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 973135000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -196353000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 1344225000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -78494000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Amortization: 16409000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 16409000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 532000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Basic EPS: 18.43
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 41806000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 33783000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -25488000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 379903000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 379903000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -38008000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 340000000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 39903000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 124962000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -3926000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 257929000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Change In Payable: -150461000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -326636000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -98132000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 338147000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 5731734000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 225000000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 1146123000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Current Assets: 5198316000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1048090000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1048090000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 2164336000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 5906000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Depreciation: 43837000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 60246000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 30123000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 13714000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Diluted EPS: 18.43
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 350114000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 0.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — EBIT: 457376000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — EBITDA: 517622000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — End Cash Position: 379952000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -16679000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 1939914000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 358178000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 12000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 56805000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 104174000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 1051629000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 2760840000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Gross Profit: 1867514000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Held To Maturity Securities: 10000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Interest Expense: 95733000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 95733000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Interest Income: 179000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 179000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -101208000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 179000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Inventory: 2078466000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 6783856000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -28840000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 50482000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Investmentsin Associatesat Cost: 49940000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 2221074000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 4032000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 4032000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Long Term Equity Investment: 49940000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 27868000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 213332000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Minority Interest: -197000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Net Debt: 672219000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income: 350114000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 350114000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 350114000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income Extraordinary: 0.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 350114000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 350114000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 361643000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 350114000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -675000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Interest Income: -103408000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -2000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 122537000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -2616000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -103408000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: -4000000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Net PPE: 2564487000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -24342000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 125153000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 5627560000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 27868000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 10401000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 518153000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Normalized Income: 350627848.70
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 383666000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Operating Income: 460362000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Operating Revenue: 3013637000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 19004000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: -1000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 79864000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 104174000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 71112000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 1000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: -1000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 989000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 723372000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Payable: 237088000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Properties: 67651000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 131000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 1709287000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Other Special Charges: -49000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Payables: 517249000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Pension And Employee Benefit Expense: -3164000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 5906000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 1702884000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Pretax Income: 361643000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 0.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -675000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -2000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -24813000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 56047000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 1146123000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 60246000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 30988000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 94657000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Research And Development: 93713000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 50000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 4056568000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 471000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 234072000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 290877000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Share Issued: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Special Income Charges: -531000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 5731734000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 5627560000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -17151.30
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Tax Provision: 11529000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.03
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 63748000.00
NATHBIOGEN.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -9221000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Assets: 7927969000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 5735766000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Debt: 1052122000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 5731734000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Total Expenses: 2553275000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 2196235000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 2729652000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 31899000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 7854000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 2805000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -531000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -531000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Trading Securities: 49940000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Work In Process: 82505000.00
NATHBIOGEN.NS balance_sheet (annual, 2023-03-31) — Working Capital: 3033980000.00
NATHBIOGEN.NS income_statement (annual, 2023-03-31) — Write Off: 580000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — +Operating Expense: 1722154000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — +Total Revenue: 3326249000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 432962000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 943086000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -175291000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 1344225000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -70400000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Amortization: 16056000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 16056000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 535000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Basic EPS: 20.85
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 379952000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 48665000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -267757000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 771334000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 771334000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -38008000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 740100000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 31234000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -224625000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -11254000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 288208000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Change In Payable: 155606000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 23014000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 230949000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 394147000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 6099187000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 408828000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 1135722000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Current Assets: 5716647000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Current Debt: 1054809000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1054809000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 2624470000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 8839000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Depreciation: 49168000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 65224000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 32612000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 16556000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Diluted EPS: 20.85
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 396185000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 2716000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — EBIT: 501934000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — EBITDA: 567158000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — End Cash Position: 774099000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -77779000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 2179694000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 478181000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -10000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 72858000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 88118000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 1013486000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 2990463000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Gross Profit: 2190527000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Held To Maturity Securities: 0.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Interest Expense: 86287000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 86287000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Interest Income: 3224000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 3224000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -91112000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 3224000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Inventory: 2303091000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 7202646000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -274012000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 60463000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Investmentsin Associatesat Cost: 59928000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 2221074000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 48650000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 48650000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 59928000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 30000000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 270574000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Net Debt: 332125000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income: 396185000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 396185000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 396185000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income Extraordinary: 34488000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 396185000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 396185000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 415647000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 396185000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: 0.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Interest Income: -88824000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -9980000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 51341000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 24238000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -88824000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: -1000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: 1000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Net PPE: 2815172000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -267256000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 27103000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 6011069000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 30000000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 12760000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 532908000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Normalized Income: 363445425.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 745938000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Operating Income: 468373000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Operating Revenue: 3326249000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 19004000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: -3000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 86127000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 88118000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 64553000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: -1000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: -1000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 1978000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 911451000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Payable: 383592000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Properties: 41322000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 1741000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1629393000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Other Special Charges: -34498000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Payables: 828743000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Pension And Employee Benefit Expense: 5065000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 8839000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 1632297000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Pretax Income: 415647000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: -34488000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: 0.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -9980000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -267757000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 69106000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 1135722000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 65224000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 34589000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 105906000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Research And Development: 112764000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 2766000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 4414745000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 501000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 276369000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 349227000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Share Issued: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Special Income Charges: 34250000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 6099187000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 6011069000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 1510425.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Tax Provision: 19462000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.04
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 62335000.00
NATHBIOGEN.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -3403000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Assets: 8802306000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 6147837000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Debt: 1103459000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 6099187000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Total Expenses: 2857876000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 2703119000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 3085659000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 78649000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 5761000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 9473000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 34250000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 34250000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Trading Securities: 59928000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Work In Process: 54291000.00
NATHBIOGEN.NS balance_sheet (annual, 2024-03-31) — Working Capital: 3092177000.00
NATHBIOGEN.NS income_statement (annual, 2024-03-31) — Write Off: 248000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 280293000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 1477084000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 232711000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 20768000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 1937006000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 6402724000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 5156188000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 1251913000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 1251913000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 1813547000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 8839000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 80138000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 2430432000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 1671421000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 7677723000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 232711000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 23086000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 23086000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 45476000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 1254231000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 2430432000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 6322586000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 0.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 19004000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 19577000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 260851000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 80138000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 385365000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 1000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 2430432000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 1916238000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Payables: 291944000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 19004000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 6402724000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 6322586000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 51100000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 8284834000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 6425810000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 1274999000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 6402724000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 1882110000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 3128646000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 68563000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 11651000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 3342641000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — +Operating Expense: 1833782000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 352172000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — +Total Revenue: 3649082000.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 519677000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 794836000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 794836000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 889015000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 889015000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -197119000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -197119000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 1344225000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1344225000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -147483000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -147483000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Amortization: 16296000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 16296000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 537000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 537000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 19165690.00
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 19004000.00
NATHBIOGEN.NS income_statement (annual, 2025-03-31) — Basic EPS: 20.14
NATHBIOGEN.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 0.42
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 774099000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 60521000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 60521000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -79204000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 190040000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 885280000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 885280000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 885280000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 885280000.00
NATHBIOGEN.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -38008000.00
NATHBIOGEN.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 870500000.00
NATHBIOGEN.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 870500000.00